Publicaciones en colaboración con investigadores/as de Universidad de Salamanca (192)

2024

  1. An algorithm for the diagnosis of betalactam allergy, 2024 update

    Allergy: European Journal of Allergy and Clinical Immunology

  2. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Haematologica

  3. Cajal’s contributions to vestibular research

    Frontiers in Neuroanatomy , Vol. 18

  4. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  5. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 17, pp. 3704-3714

  6. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

  7. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

  8. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)

    Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284

  9. Rafael Lorente de Nó (1902–1990)

    Journal of Neurology, Vol. 271, Núm. 7, pp. 4727-4729

  10. Relationship between cholestasis and altered progesterone metabolism in the placenta-maternal liver tandem

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 2

  11. SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

    Cell Reports, Vol. 43, Núm. 3

  12. Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3

    Biomedicine and Pharmacotherapy, Vol. 180

  13. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

  14. Strategies to enhance the response of liver cancer to pharmacological treatments

    American journal of physiology. Cell physiology, Vol. 327, Núm. 1, pp. C11-C33

2023

  1. Characterization of three predicted zinc exporters in Brucella ovis identifies ZntR-ZntA as a powerful zinc and cadmium efflux system not required for virulence and unveils pathogenic Brucellae heterogeneity in zinc homeostasis

    Frontiers in Veterinary Science, Vol. 10

  2. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  3. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  4. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  5. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  6. If You're Not Confused, You're Not Paying Attention: Ochrobactrum Is Not Brucella

    Journal of clinical microbiology, Vol. 61, Núm. 8, pp. e0043823